Cargando…
The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma
Meningioma is the most common primary intracranial tumour, and surgical resection is the main therapeutic option. Merlin is a tumour suppressor protein that is frequently mutated in meningioma. The activity of the E3 ubiquitin ligase complex, CRL4-DCAF1, and the Raf/MEK/ERK scaffold protein Kinase s...
Autores principales: | Lyons Rimmer, Jade, Ercolano, Emanuela, Baiz, Daniele, Makhija, Mahindra, Berger, Allison, Sells, Todd, Stroud, Steve, Hilton, David, Adams, Claire L., Hanemann, C Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407567/ https://www.ncbi.nlm.nih.gov/pubmed/32629964 http://dx.doi.org/10.3390/cancers12071744 |
Ejemplares similares
-
GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma
por: Negroni, Caterina, et al.
Publicado: (2020) -
Constitutive activation of the EGFR–STAT1 axis increases proliferation of meningioma tumor cells
por: Ferluga, Sara, et al.
Publicado: (2020) -
Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas
por: Sofela, Agbolahan A., et al.
Publicado: (2021) -
Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target
por: Bassiri, Kayleigh, et al.
Publicado: (2017) -
MLN8054 and Alisertib (MLN8237): Discovery of Selective
Oral Aurora A Inhibitors
por: Sells, Todd B., et al.
Publicado: (2015)